Evidence map›Paper›PMID 26993779›Full record

SynthesisOncotarget2016

Systematic evaluation of cancer risk associated with rs2292832 in miR‑149 and rs895819 in miR‑27a: a comprehensive and updated meta‑analysis.

Yajing Feng, Fujiao Duan, Chunhua Song, Xia Zhao, Liping Dai, Shuli Cui

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Association ofBiomedicines · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yajing FengDepartment of Infection Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, P.R.China.
Fujiao DuanDepartment of Hospital Infection Management, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, P.R.China.
Chunhua SongDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, P.R.China.
Xia ZhaoDepartment of Hospital Infection Management, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, P.R.China.
Liping DaiDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, P.R.China.
Shuli CuiCollege of Professional Study, Northeastern University, Boston, 02215 Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study is to provide a precise quantification for the association between miR-149 T > C (rs2292832) and miR-27a A > G (rs895819) and the risk of cancer. We conducted a systematic literature review and evaluated the quality of included studies based on Newcastle-Ottawa Scale (NOS). Pooled odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were calculated to assess the strengths of the associations. We identified 40 studies for pooled analyses. Overall, the results demonstrated that the rs2292832 polymorphism was subtly decrease the risk of breast cancer (CT + CC vs TT: OR = 0.83, 95% CI: 0.70-0.98, P = 0.03; CC vs CT + TT: OR = 0.80, 95% CI: 0.68-0.93, P = 0.00), and the rs895819 polymorphism wasassociated with significantly increased cancer risk in the Asian population (AG + GG vs AA: OR = 1.24, 95% CI: 1.03-1.50, P = 0.02) and in colorectal cancer subgroup (GG vs AA: OR = 1.45, 95% CI: 1.10-1.92, P = 0.00; AG + GG vs AA: OR = 1.35, 95% CI: 1.15-1.58, P = 0.00; GG vs AG + AA: OR = 1.36, 95% CI: 1.04-1.77, P = 0.02). In addition, a subtly decreased risk was observed in the Caucasian population and in breast cancer subgroup. In conclusion, the rs2292832 polymorphism was significantly associated with increased breast cancer risk, and the rs895819 polymorphism contributes to the susceptibility of colorectal and breast cancer.

Indexed as

Genetic Predisposition to DiseaseGenotypeHumansMicroRNAsNeoplasmsOdds RatioPolymorphism, Single NucleotideRisk FactorsMicroRNAsMIRN149 microRNA, humanMIRN27 microRNA, humancancermiR-149miR-27asusceptibilitysystematic evaluation

Identifiers

PMID26993779
PMCPMC5008366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.